Neurotech International Limited
On 12 September 2016 (“Prospectus Date”), Neurotech International Limited (ACN 610 205 402) (“Neurotech” or “the Company”) lodged a prospectus (“Prospectus”) with the Australian Securities and Investments Commission (“ASIC”) for the offer of 35,000,000 fully paid ordinary shares in the Company (“Shares”) at an issue price of 20 cents per Share to raise $7,000,000, and the offer of up to 2,529,076 options to acquire Shares to the Lead Manager (as those terms are defined in the Prospectus).
THE OFFER HAS NOW CLOSED, AND THE COMPANY IS NO LONGER ACCEPTING APPLICATIONS FOR SHARES.
An electronic copy of the Prospectus can be obtained in PDF format by clicking below after confirming agreement to the following.
This is an important document that should be read in its entirety. If you do not understand it, you should consult your professional adviser without delay. The paper form of the electronic Prospectus is accessible through this website has been lodged with ASIC.
Applications for securities referred to in the Prospectus must be made in accordance with the terms and conditions set out in the Prospectus. Applications for securities must be made on an application form that accompanies a complete hard copy of the Prospectus. There is no facility for online applications.
The Company will not issue any Shares on the basis of this Prospectus later than 13 months after the Prospectus Date.
The Prospectus does not constitute an offer in any place in which, or to any person to whom, it will not be lawful to make such an offer. No action has been taken to lodge, register or file the Prospectus in any jurisdiction outside Australia. The distribution of this Prospectus outside Australia may be restricted by law and persons who come into possession of this Prospectus outside Australia should seek advice on and observe any such restrictions. The investment described in this Prospectus has not been recommended by any regulatory authority of any jurisdiction including ASIC.
The information on this website is provided for information purposes only and is subject to change without notice. Nothing contained on this website or in the Prospectus constitutes investment, legal, accounting, business, tax or other advice. The information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs. The information on this website does not form part of the Prospectus.
By accessing the Prospectus, you are taken to have confirmed that you have read and understood the notice and agree to these terms and conditions.
Who is Neurotech?
The Neurotech Group of companies, or Neurotech, is a medical device and solutions company incorporated in Australia, operating through its wholly-owned, Malta-based subsidiary, AAT Research.
Neurotech is developing neuro-stimulation and neuro-diagnostic solutions to be delivered via the Mente platform, an innovative platform technology to enable medical practitioners to remotely monitor and play an active role in home-based therapies.
Neurotech’s first product, Mente Autism, assists with the management of children with Autism Spectrum Disorder (ASD).
What is Neurotech’s core technology?
Neurotech’s first product, Mente Autism, is a portable, electroencephalographic (EEG) medical device for home use in the form of a headband that uses closed-loop neurofeedback to help relax the minds of children with ASD. Mente Autism is simple to use, affordable, is built on clinical grade technology and is effective.
For further information on Mente Autism, please click here
Where is Neurotech based?
The holding company, Neurotech International Limited, is incorporated in Australia while the Company’s operating subsidiaries, of which the main subsidiary is AAT Research, is based in Malta.
What is Mente Autism?
Mente Autism is a is a portable, electroencephalographic (EEG) medical device for home use to help relax the minds of children with ASD. Mente Autism is simple to use, affordable, is built on clinical grade technology and is effective.
For further information on Mente Autism, please click here
How does it work?
Mente Autism uses unique and award-winning technology to help relax the minds of children with ASD, enabling them to better focus and engage positively with their environment.
The neurofeedback system in Mente Autism takes clinical grade technology and brings this into safe home application. The device reads the user’s brain activity to identify and suppress abnormally high brainwaves that are typically found in children on the autism spectrum, by creating personalized auditory stimulation to reduce unwanted signals. This can be compared to noise-reduction headphones, which create counter-noise to eliminate undesirable external noise. The reduction in the user’s brainwaves via this daily therapy helps relax the user’s mind, which in turn brings about enhanced concentration and communication.
Where is Mente Autism available?
Neurotech is initially targeting European markets with the Mente Autism device. The latest version of the product will be launched in Italy in late 2016. The UK, Germany and France are expected to be the next target markets with North America, Australia and emerging markets to follow thereafter.
What certifications have been received for the Mente device?
Mente 2, the predecessor to Mente Autism, has received CE Marking and is FDA listed, while Neurotech subsidiary AAT Medical is ISO certified. Neurotech expects to receive CE Marking for Mente Autism in the third quarter of 2016.
What other technology or products is Neurotech developing?
In line with Neurotech’s vision of becoming the global leader in home-use and clinical neurotechnology solutions, Neurotech has a pipeline of future potential products currently under research and development which will all be delivered via the Mente platform and integrate with the Mente Cloud.
These products are split between the business-to-consumer (B2C) or end user/consumer family of products for home-use such as Neurotech first product, Mente Autism, and the business-to-business (B2B) or business-focused family of products for clinical use.
Subject to continued research and development, the B2B line will include an in-hospital medical professional product offering and a non-invasive electrotherapy stimulation application to treat different conditions. This B2B offering is planned to comprise a hardware element, Mente Pro, and a software platform, Mente Suite, that would enable medical practitioners to apply different therapies using Mente Pro in a clinical setting as well as allowing them to analyse, monitor and intervene via Mente Cloud in home-based therapies in use by their patients who use the Mente B2C line of products.
For any further questions or enquiries you may have, please visit our contact page here.